Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 224,352,432 papers from all fields of science
Search
Sign In
Create Free Account
MK 458
Known as:
2H-Naphth(1,2-b)-1,4-oxazin-9-ol, 3,4,4a,5,6,10b-hexahydro-4-propyl-, hydrochloride, (4aR-trans)-
, MK-458
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
Oxazines
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
1993
1993
Poor tolerability of MK-458.
N. Cutler
,
J. Sramek
,
G. Block
Archives of Neurology
1993
Corpus ID: 39468422
To the Editor. —We were pleased to read the article entitled "Dopamine Agonist Treatment of Fluctuating Parkinsonism," 1 which…
Expand
1991
1991
Parkinson's Disease Monotherapy With Controlled‐Release MK‐458 (PHNO): Double‐Blind Study and Comparison to Carbidopa/Levodopa
J. Ahlskog
,
M. Muenter
,
Patricia A. Bailey
,
P. M. Miller
Clinical neuropharmacology
1991
Corpus ID: 7256796
SummaryThe potent and selective dopamine D-2 agonist, MK-458 [PHNO; ( + )-4-propyl-9-hydroxynaphthoxazine] was administered as…
Expand
1991
1991
Effect of MK-458 (HPMC) in Parkinson's disease previously untreated with dopaminergic drugs. A double-blind, placebo-controlled multicenter study.
W. Koller
,
G. Block
,
+7 authors
L. Mclean
Clinical neuropharmacology
1991
Corpus ID: 24097945
Ninety-four patients with early Parkinson's disease were investigated in a double-blind, placebo-controlled evaluation of MK-458…
Expand
1988
1988
MK 458, a selective and potent D2 receptor agonist in advanced Parkinson's disease.
A. Lieberman
,
L. Chin
,
G. Baumann
Clinical neuropharmacology
1988
Corpus ID: 36038567
MK 458 is a potent and selective D2 receptor agonist. MK 458 consists of (+)-4-propyl-9-hydroxynaphthoxazine (PHNO) in a…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE